Two Stocks That Achieved Incredible Growth in the Last Decade

Investing in growth-oriented businesses can lead to great returns, especially if they focus on growing areas of the economy. Two stocks that have achieved phenomenal growth in the past decade are DexCom (NASDAQ: DXCM) and Tesla (NASDAQ: TSLA). Investing $40,000 into either stock ten years ago would have resulted in a portfolio worth over $1 million today.

DexCom is a healthcare company that produces continuous glucose monitoring (CGM) devices to help people manage their blood glucose levels. With diabetes being a growing concern for the healthcare industry, DexCom has experienced significant growth over the past decade. The company's top line has soared, and it is now consistently profitable. DexCom's future looks promising as it continues to produce newer, smaller CGM devices. While it may not produce the same returns as the past decade, it is still a great stock to hold given the ongoing need for diabetes management.

Tesla, a leading electric vehicle maker, has achieved even more impressive growth over the past decade. In 2012, Tesla's revenue had more than doubled from the previous year, but the company was deeply unprofitable. Now, Tesla is a top company, generating billions in revenue and earning a profit. The company has established itself as a leader in the electric vehicle market, which is expected to grow at an annualized rate of about 24% through 2028. With concerns about climate change and the need for more environmentally friendly cars, Tesla can continue to be a great growth stock. However, there are risks involved, such as growing competition and the possibility that developing fully autonomous vehicles may not happen. Despite these risks, Tesla can still be a good buy, especially with the stock down 50% from its 52-week high.

In conclusion, investing in growth-oriented businesses that focus on growing areas of the economy can lead to great returns. DexCom and Tesla have proven this over the past decade, and while their future growth may not replicate the gains of the past decade, they can still be good buys.